|Bid||8,681.00 x 0|
|Ask||8,684.00 x 0|
|Day's range||8,507.00 - 8,710.00|
|52-week range||6,499.80 - 8,848.00|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||41.65|
|Earnings date||12 Nov 2021|
|Forward dividend & yield||2.02 (2.36%)|
|Ex-dividend date||12 Aug 2021|
|1y target est||N/A|
AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.
The company's next-generation treatment for breast cancer could become the new standard of care.
By Dhirendra Tripathi